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Abstract
Background: The insulin-degrading enzyme gene (IDE) is a strong functional and positional candidate for late onset
Alzheimer’s disease (LOAD).
Methodology/Principal Findings: We examined conserved regions of IDE and its 10 kb flanks in 269 AD cases and 252
controls thereby identifying 17 putative functional polymorphisms. These variants formed eleven haplotypes that were
tagged with ten variants. Four of these showed significant association with IDE transcript levels in samples from 194 LOAD
cerebella. The strongest, rs6583817, which has not previously been reported, showed unequivocal association
(p=1.5610
28, fold-increase=2.12,); the eleven haplotypes were also significantly associated with transcript levels (global
p=0.003). Using an in vitro dual luciferase reporter assay, we found that rs6583817 increases reporter gene expression in
Be(2)-C (p=0.006) and HepG2 (p=0.02) cell lines. Furthermore, using data from a recent genome-wide association study of
two Croatian isolated populations (n=1,879), we identified a proxy for rs6583817 that associated significantly with
decreased plasma Ab40 levels (ß=20.124, p=0.011) and total measured plasma Ab levels (b=20.130, p=0.009). Finally,
rs6583817 was associated with decreased risk of LOAD in 3,891 AD cases and 3,605 controls. (OR=0.87, p=0.03), and the
eleven IDE haplotypes (global p=0.02) also showed significant association.
Conclusions: Thus, a previously unreported variant unequivocally associated with increased IDE expression was also
associated with reduced plasma Aß40 and decreased LOAD susceptibility. Genetic association between LOAD and IDE has
been difficult to replicate. Our findings suggest that targeted testing of expression SNPs (eSNPs) strongly associated with
altered transcript levels in autopsy brain samples may be a powerful way to identify genetic associations with LOAD that
would otherwise be difficult to detect.
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Introduction
Late onset Alzheimer’s disease (LOAD) is the most common
cause of dementia in the elderly affecting approximately 10% of
those over the age of 65 years. LOAD is a neurodegenerative
condition in which the brain develops large numbers of
extracellular senile plaques composed primarily of aggregated
amyloid-ß proteins (Aß) as well as intraneuronal neurofibrillary
tangles composed mainly of aggregated tau protein [1]. Mutations
in the APP, PSEN1, and PSEN2 genes that increase production of
Aß are known causes of the rare, early onset, familial form of AD
(for review see ref. [2]). Twin studies indicate that genetic factors
are also important in late onset AD and account for at least 60% of
its phenotypic variance [3,4]. The APOE e4 allele, which is present
in ,50% of AD cases, is associated with a substantial increase in
the risk of LOAD, but it is neither necessary nor sufficient for the
development of AD [5–7]. Despite an intense search in the past
decade, identification of the additional genes that contribute to
phenotypic variance in LOAD has proven difficult. Promising new
LOAD genes such as SORL1 [8], GAB2 [9], PCDH11X [10],
PICALM [11], CLU [11,12] and CR1 [11,12] are, however,
now being identified through genome-wide association studies
and follow-up analyses in large case-control series. Here, we
evaluate variants in IDE for association with LOAD and with
two additional endophenotypes that have important functional
implications.
IDE is a strong functional LOAD candidate gene because it
encodes the insulin degrading enzyme, which has been shown
to degrade Aß [13–17] and to influence brain Aß levels in vivo
[18–20]. IDE has also obtained much attention as an LOAD
candidate gene because of its location near LOAD linkage peaks.
The IDE gene is located on chromosome 10q23.33, very near a
‘suggestive’ linkage peak (chromosome 10q24) found in two
genome-wide linkage studies of LOAD families [21,22] and a
‘significant’ linkage peak (10q) in a third [23]. The latter study
showed allele-specific association of a variant (D10S583) within
195 kb of IDE with LOAD, an association that was confirmed by
independent follow-up analysis in an LOAD case-control series
[24]. Independent haplotype analysis by Prince et al. of a 276-kb
block encompassing IDE showed highly significant association
with LOAD and with several intermediate LOAD phenotypes in
multiple case-control series [25]. When we performed follow-up
analysis on these haplotypes [26], we found highly significant
association with LOAD in one case-control series and significant
association with plasma Ab42 levels in extended LOAD families.
These findings were supported by an independent study that
associated IDE variants with Ab plaque density and cognitive
function in three independent Swedish LOAD series and in a
follow-up English series [27], although the variants were not
directly associated with disease risk.
Many IDE variants, including those studied by Prince et al. and
by our group, have been analyzed in additional follow-up studies
of Caucasian [27–38], Japanese [39], and Han Chinese [40] case-
control series. Some of these studies showed significant evidence
for association [29,30,33,34,36,40] whereas others did not
[27,28,31,32,35,37–39]. AlzGene (www.alzforum/alzgene) meta-
analysis of 12 variants from 21 publications investigating IDE to
date shows no significant association.
Overall, studies of IDE variants provide evidence for association
with LOAD that is difficult to dismiss as a set of false positives, but
the association is not compelling because replication is inconsistent
and the results of meta-analyses do not achieve significance [41].
Results
Using dHPLC followed by sequencing, we screened conserved
regions ($70% identity identity in human vs rodent sequence) in
the IDE gene and in 10 kb of 59 and 39 flanking sequence for
variants likely to be functional. In each of the 521 subjects
screened (269 cases and 252 controls), we evaluated 40 amplicons
that contained a total of 9,501 bp of conserved DNA. This DNA
included all exons (5,954 bp), conserved regions in the 59 (268 bp)
and 39 (1,465 bp) flanking regions, and 1,814 bp of highly
conserved intronic sequence. This search (Table S1 online)
yielded 17 common polymorphisms (minor allele frequencies
.0.01) likely to have functional effects (Table S2 and Figure S1
online). These variants and the haplotypes they form were tested
for association with IDE mRNA expression using transcript levels
measured in 194 LOAD cerebella sampled at autopsy from the
brain bank at Mayo Clinic, Jacksonville. They were also analyzed
for genetic association with LOAD in one of the largest LOAD
case-control series studied to date, which consisted of 3,529 AD
cases and 3,441 controls drawn from four American and five
North European series.
The 17 IDE variants formed eleven haplotypes with frequencies
.1% that could be tagged with ten variants (Tables S3 and S4
online). In the combined series, these haplotypes (Table 1) were
significantly associated with IDE transcript levels (global p=0.003)
and with LOAD (global p=0.02). Of the ten tagging variants, four
showed significant association with the level of IDE transcript
(Table 2). Association was most significant for v311 (rs6583817)
and v3 (rs5786996) with p-values of 1.5610
28 and 0.0005
respectively, and linear regression showed that for both of these
variants the average level of IDE transcript was more than 2-fold
higher for each minor allele carried. In the combined series, the
minor alleles of v311 (p=0.03) and v3 (p=0.02) were also
associated with reduced risk of LOAD. Notably, neither variant
has previously been analyzed for association with LOAD, so they
are not included in the AlzGene database. The association of these
two variants with LOAD showed no series-related effects. Results
for each of the eight series that were tested are shown in Figure 1A
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level of IDE transcript in carriers of these two variants as
compared to non-carriers.
Additional discussion of the complex single variant and
haplotype associations shown in Table 1 and Figure 1 is
provided in the Text S1 online. There, we consider two
contrasting models; a simple model where v311 is postulated to
be the only variant that influences IDE function and a more
complex model where multiple haplotypes would have indepen-
dent effects. We emphasize that the current study has inadequate
power to distinguish between these models.
We further explored the involvement of IDE in LOAD
pathogenesis by evaluating the effect of IDE on Aß levels. To
this end, we analyzed plasma Aß40, Aß42 and total Aß (Aß40 +
Aß42) in 949 individuals from Vis and 930 individuals from
Korcula (total=1,879), which are two isolated populations from
the Dalmatian islands recently analyzed for multiple disease
related traits using genome-wide scans [42–44].
Table 1. Association of IDE common conserved haplotypes with cerebellar IDE mRNA and LOAD.
Htype Freq Variant ID
Association with IDE mRNA
(n=194 autopsy LOAD
cerebellum; global p=0.003)
Association with LOAD
(LOAD=3,529, CTRL=
3,441; global p=0.02)
2 3 6 154 310 311 176 46 684 685 b Fold D (95% CI) p OR (95% CI) p
H1 0.24 0 0 0 0 0 0 0 0 0 0 0.08 0.94 (0.75–1.19) 0.62 0.95 (0.86–1.05) 0.32
H2 0.19 0 0 0 0 0 0 0 0 0 1 0.34 0.79 (0.64–0.98) 0.03 1.09 (0.98–1.21) 0.13
H3 0.1 0 0 0 1 0 0 1 1 0 0 0 1.00 (1.00–1.00) 0.85 0.94 (0.82–1.08) 0.40
H 4 0 . 1 1 0010 0000 0020.16 1.11 (0.77–1.61) 0.56 0.97 (0.85–1.11) 0.64
H5 0.1 0 0 0 1 0 0 0 1 0 0 0 1.00 (1.00–1.00) 0.49 1.23 (1.06–1.41) 0.005
H 6 0 . 0 9 0001 0100 0021.16 2.24 (1.56–3.21) 1.0610
25 0.89 (0.77–1.03) 0.11
H 7 0 . 0 5 0000 0001 0020.17 1.12 (0.75–1.67) 0.57 1.11 (0.91–1.35) 0.32
H8 0.05 0 0 0 0 0 0 0 0 1 0 0.12 0.92 (0.60–1.41) 0.71 0.89 (0.73–1.08) 0.25
H 9 0 . 0 4 0101 0100 0021.22 2.34 (1.28–4.27) 0.006 0.79 (0.63–0.99) 0.04
H10 0.02 1 0 0 1 0 0 0 0 0 0 0.19 0.88 (0.47–1.63) 0.68 1.26 (0.95–1.68) 0.11
H11 0.02 0 0 0 0 1 0 0 0 0 0 0.25 0.84 (0.45–1.56) 0.58 1.14 (0.82–1.58) 0.44
Haplotypes are numbered according to their frequency. Only haplotypes with frequency .0.01 are shown. The ‘‘Haplotype’’ and ‘‘Variant ID’’ columns show the allelic
composition of each haplotype in the 59 to 39 orientation from the p to the q telomere of chromosome 10. The allelic composition of each haplotype is depicted as ‘‘0’’
for no minor allele and ‘‘1’’ for minor allele. Freq=haplotype frequency in the combined series. Haplotype linear regression analyses vs. IDE mRNA levels were performed
using an additive model adjusting for APOE e4 dosage, age at diagnosis/entry and sex. b=regression coefficient. Fold difference in expression is derived from the term
(2
(2b)). 95% confidence intervals (CI) were derived from the term 2
[2(b6SEM)]; p=p value. Haplotype logistic regression analyses vs. LOAD were carried out using an
additive model adjusting for APOE e4 dosage, age at diagnosis/entry, sex and series. OR=odds ratio.
doi:10.1371/journal.pone.0008764.t001
Table 2. Association of IDE common conserved variants with cerebellar IDE mRNA and LOAD.
Variant details
Association with IDE
mRNA (n=194 LOAD
autopsy cerebellum)
Association with LOAD
(LOAD=3,529; CTRL=3,441)
ID rs number Position Location Cons. MAF HWE-p 1 2 b Fold D (95% CI) p AD CTRL OR (95% CI) p
2 N/A 94,202,383 39 flank 81% 0.02 0.15 AA – 20.03 1.02 (0.60–1.74) 0.94 0.02 0.02 1.15 (0.88–1.50) 0.30
3 rs5786996 94,202,516 39 flank 74% 0.04 0.04 - C 21.08 2.12 (1.40–3.21) 0.0005 0.03 0.04 0.77 (0.62–0.95) 0.02
6 rs5786997 94,203,071 39 flank 88% 0.11 0.93 – AT 20.09 1.07 (0.78–1.45) 0.69 0.1 0.11 0.96 (0.84–1.09) 0.52
154 rs4646957 94,219,892 Intron18 71% 0.36 0.88 G A 20.28 1.22 (1.03–1.43) 0.02 0.35 0.36 0.98 (0.90–1.07) 0.67
310 N/A 94,236,972 Exon13 92% 0.08 1 G T 20.22 1.16 (0.68–1.98) 0.58 0.02 0.02 1.09 (0.80–1.48) 0.60
311 rs6583817 94,237,227 Intron12 74% 0.13 0.6 G A 21.08 2.12 (1.65–2.71) 1.5610
28 0.12 0.13 0.87 (0.78–0.99) 0.03
176 rs17875327 94,264,789 Intron4 85% 0.1 0.01 T C 0.18 0.88 (0.67–1.15) 0.35 0.1 0.10 0.97 (0.84–1.10) 0.61
46 rs4646955 94,284,271 Intron3 76% 0.25 0.14 T C 0.10 0.93 (0.78–1.12) 0.46 0.26 0.25 1.07 (0.98–1.17) 0.14
684 rs17107721 94,288,480 Intron1 71% 0.05 0.72 G A 20.07 1.05 (0.73–1.50) 0.8 0.05 0.05 0.88 (0.73–1.06) 0.18
685 rs11187061 94,295,389 Intron1 70% 0.18 0.57 C T 0.35 0.78 (0.65–0.94) 0.009 0.19 0.18 1.07 (0.96–1.18) 0.20
Variant IDs and rs numbers (dbSNP variant identifier) are given for the 10 tagging variants; Chr position indicates relative position to the Human Genome build 36.1.
Cons=conservation ($70% identity between the human and mouse sequence); MAF=minor allele frequency in controls; HWE-p=Hardy-Weinberg Equilibrium p value
in controls; columns labeled as 1 and 2 indicate the major and minor allele, respectively. Single variant linear regression analyses vs. IDE mRNA levels were performed
using an additive model adjusting for APOE e4 dosage, age at diagnosis/entry and sex. b=regression coefficient. Fold difference in expression due to a single copy of
the minor allele is derived from the term (2
(2b)). 95% confidence intervals (CI) were derived from the term 2
[2(b6SEM)]; p=p value. Single variant logistic regression
analyses vs. LOAD were carried out using an additive model adjusting for APOE e4 dosage, age at diagnosis/entry, sex and series. OR=odds ratio.
doi:10.1371/journal.pone.0008764.t002
IDE eSNP, Ab Levels and AD Risk
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8764Our analysis took advantage of the strong linkage disequilibri-
um between v311 and rs7910977 (r2=0.996 and D9=1), since
rs7910977, but not v311, was included in the genome-wide scan.
This analysis (Table S5 online) showed that rs7910977 was
significantly associated with reduced levels of plasma Aß40 in the
Vis population (ß 6 SE=20.14760.06 p=0.018) and sugges-
tively associated with reduced Ab40 in the Korcula population
(ß 6 SE=20.08660.08, p=0.27). Meta-analysis of the two
populations showed overall significant association with reduced
Aß40 (ß 6 SE=20.12460.05, p=0.011). Analysis of the two
populations (Table S5 online) also showed a suggestive associa-
tion between rs7910977 and reduced plasma Aß42 levels (meta-
Figure 1. Association of variants 3 (rs5786996) and 311 (rs6583817) with LOAD and IDE mRNA levels. (A) Variants were analyzed for
association with LOAD using an additive logistic regression model with age at diagnosis/entry, sex and APOE e4 dosage as covariates. N; total
genotype count, MAF; minor allele frequency. For logistic regression of the combined series, individual series were included as covariates. P values
demonstrating that there were no series-related effects on association (p*) were obtained by comparing this model to one that adjusts for series x
genotype interactions in addition to age at diagnosis/entry, sex, APOE e4 dosage, and series effects. (B) OR and 95% CI forest plots were generated
from the data tabulated in panel a. (C) Association of the two variants with IDE mRNA levels in cerebellum. The horizontal black line and dots
represent median relative IDE mRNA level expressed as 2
2DDCt for each variant. Boxes represent the 25th and 75th percentiles and whiskers represent
the full data range.11=homozygotes for the major allele, 12=heterozygotes, 22=minor allele homozygotes. Samples with 12 and 22 genotypes for
rs6583817 were combined because only two samples were 22. Variants were analyzed for association with the level of IDE transcript (DCT) using an
additive linear regression model with age at diagnosis/entry, sex and APOE e4 dosage as covariates.
doi:10.1371/journal.pone.0008764.g001
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total Aß (Aß40 +Aß42) revealed significant association with
reduced levels in the Vis population (ß 6 SE=20.16560.06,
p=0.011) and meta-analysis of the two populations showed
overall significant association with reduced total Aß (ß 6
SE=20.13060.05, p=0.009) Thus the variant that showed
strongest association with elevated IDE expression also showed
significant association with reduced levels of Aß, a substrate of
the insulin degrading enzyme that is implicated in LOAD
pathogenesis.
The analysis described in our Text S1 online indicates that our
results could all be accounted for by a simple model where v311 is
the only variant that influences IDE function. For this reason and
because v311 showed the strongest association with increased level
of IDE transcript, we evaluated its functional effect on reporter
gene expression in vitro (unlike rs7910977, v311 is located in a
conserved region of IDE and is therefore more likely to be a
functional variant). Two immortalized human cell lines (Be(2)-C
neuroblastoma and HepG2 hepatocytoma) were transfected with
expression constructs containing IDE sequence surrounding v311.
Major (G) and minor (A) allele sequences were cloned either 59 to
the promoter or 39 to the gene. In neuroblastoma (Be(2)-C) cells
(Figure 2A), transfection of the 59A (minor allele) construct
significantly increased reporter gene expression compared to the
59G (major allele) construct (59Av s5 9G=1.35-fold increase in
reporter expression, p=0.006, n=5). This result replicated well in
HepG2 hepatocellular carcinoma cells (Figure 2B:5 9Av s
59G=1.31-fold increase in reporter expression, p=0.02, n=3).
In Be(2)-C cells the same allele-specific reporter expression was
observed for the 39 constructs (39Av s3 9G fold-increase=1.35,
p=0.05), but this was not apparent in HepG2 cells (39Av s3 9G
fold-change=0.98, p=0.44). This analysis of reporter gene
expression focuses on the effect of the v311 locus in two cell lines
where regulation of IDE expression is likely to be different than in
human cerebellum. The results of this analysis do, nonetheless,
provide useful supporting evidence that v311 is a functional
variant that acts to increase IDE gene expression thereby
decreasing Aß and decreasing risk for LOAD.
Variant 3 (v3) is in near perfect linkage disequilibrium with v311
but it occurs less frequently that v311. Thus v3 tags only one of the
two haplotypes that include v311 (H9 but not H6), and both
haplotypes show essentially identical association with the level of
IDE transcript in brain (Table 1). Our point estimates of ORs for
the association of v3 and v311 with LOAD (Table 2) suggest that
v3 may have a stronger protective effect than v311, but the 95%
CIs for the ORs of these two variants are completely overlapping.
Thus we have insufficient power to determine whether the
protective effects of the two variants are truly different, and the
association of v3 with increased IDE transcript and reduced risk of
LOAD could be due entirely to a functional effect of v311.
To determine if v3 might also contribute functionally to
increased IDE expression, we evaluated its functional effect on
reporter gene expression in vitro. Two immortalized human cell
lines (Be(2)-C neuroblastoma and HepG2 hepatocytoma) were
transfected with expression constructs containing 248bp of IDE
sequence surrounding v3. In Be(2)-C cells (Figure 3A), transfec-
tion of the minor allele (C) construct significantly decreased
reporter gene expression compared to the major allele (-) construct
in both 59 and 39 locations (59Cv s5 9-; fold-change=0.77,
p=0.03, 39Cv s3 9-; fold-change=0.29, p=0.0001). This result
was replicated in HepG2 cells (Figure 3B:5 9Cv s5 9-; fold-
change=0.67, p=0.02, 39Cv s3 9-; fold-change=0.26,
p=0.0008).
These results showing that v3 is associated with decreased
expression in vitro make it unlikely that v3 functions to increase
IDE expression in brain and suggest that the association of v3 with
increased transcript in brain and reduced risk of LOAD may be
due to its strong linkage disequilibrium with v311. These results
underscore the limitation of pursuing SNP/transcript associations
observed in human brain by analyzing reporter gene expression in
cell lines where regulation may differ considerably from that in
brain. The mechanism of the increased expression we observed in
Figure 2. In vitro functional effects of variant 311 (rs6583817) on reporter gene expression. pGL3P constructs containing v311 sequence
were transfected into (A) Be(2)-C and (B) HepG2 cell lines. 59 and 39 refer to the position of the cloned sequences relative to the luciferase gene and
promoter in the pGL3P vector. G refers to vectors containing v311 major allele sequence and A refers to vectors containing v311 minor allele
sequence. P refers to the pGL3P positive control vector (containing SV40 promoter) and B refers to the pGL3B negative control vector (containing no
promoter). Error bars represent SEM (standard error of the mean). Note that the major allele sequence encompassing v311 had a repressor effect in
Be(2)-C cells that achieved significance when the 39G construct was compared to the pGL3P positive control vector (P) alone (fold-change=0.48,
p=0.04). In contrast, the wild type sequence had a significant enhancer effect when the 39G construct was compared to pGL3P in HepG2 cells (59G
fold-change=2.4, p=0.02, 39G fold-change=1.5). This difference probably reflects differential regulation of IDE expression by the transcription
factors expressed in each cell line.
doi:10.1371/journal.pone.0008764.g002
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brain are uncertain.
Discussion
We incorporated several elements into the design of this study
that were intended to improve our ability to determine whether or
not IDE has LOAD susceptibility alleles. First, we focused on
variants in conserved regions. Like other markers, these variants
can detect un-typed functional variants indirectly through linkage
disequilibrium. They are advantageous because they are more
likely to play a functional role in disease development than
anonymous polymorphisms and are therefore expected to have
higher power to detect genetic associations. Second, in an effort to
detect the net effect of associations from multiple variants, we
tested for global haplotypic association. Third, we tested these IDE
haplotypes and variants for association with IDE gene expression
levels. Fourth, we evaluated a large series of 3,529 cases and 3,441
controls to increase our power to detect weak associations with
LOAD. Finally, we used results from a separate genome wide scan
to test for association with the level of Aß40, Aß42 and the sum of
the two, in plasma.
Because it is a single test, it is reasonable to minimize multiple
testing of the 17 variants identified in conserved regions by
beginning with global tests of haplotypic association. This
approach was effective. Global haplotypic association with the
level of IDE transcript was highly significant (p=0.003), and global
haplotypic association with LOAD was also significant (p=0.02).
Testing for association with the level of IDE transcript was also
useful at the single variant level. The variants showing strongest
association were v311 (p=1.5610
28) and v3 (p=0.0005). These
significant, functionally meaningful associations provide a power-
ful rationale for prioritizing the testing of the 17 IDE variants for
association with LOAD beginning with these two expression SNPs
(eSNPs). When assessed in the LOAD case-control series, these
variants did in fact show significant (p,0.03) association with
reduced risk of LOAD.
It is likely that some LOAD susceptibility alleles alter gene
function similarly in affected and unaffected brain regions and
even in peripheral tissues and lymphoblastoid cell lines, whereas
others alter gene function selectively in affected brain regions. In
this study, we analyzed IDE mRNA in LOAD brain tissue
obtained at autopsy to improve detection of LOAD-related IDE
variant/transcript associations that might go undetected in
peripheral tissues or lymphoblastoid cell lines. Because LOAD
causes profound neuronal cell loss and astrogliosis that will alter
mRNA levels in affected regions, mRNAs were measured in the
cerebellum which is largely unaffected by LOAD pathology. This
approach presupposes that at least some IDE variant/transcript
associations relevant to LOAD can be detected not only in affected
brain regions but also in cerebellum. mRNAs are degraded in the
postmortem interval, and mRNA levels are likely to be influenced
by the agonal state prior to death. These factors will alter IDE
transcript level, but they can have a similar effect in carriers and
non-carriers of functionally important variants that does not alter
the difference in transcript level between carriers and non-carriers.
This probably explains why we were able to detect unequivocal,
functionally meaningful IDE variant/transcript associations using
samples obtained at autopsy from only 194 subjects.
Collectively our findings provide the best evidence to date that
IDE has susceptibility alleles for LOAD. More generally, they
suggest that targeted testing of expression SNPs (eSNPs) strongly
associated with altered transcript levels in brain samples frozen at
autopsy may be a powerful way to identify genetic associations
with CNS diseases that would otherwise be difficult to detect.
Materials and Methods
Ethics Statement
Approval was obtained from the ethics committee or institu-
tional review board of each institution responsible for the
ascertainment and collection of samples (Mayo Clinic College of
Medicine, Jacksonville, FL and Mayo Clinic College of Medicine,
Rochester, MN, USA; MRC Human Genetics Unit, Western
General Hospital and the University of Edinburgh Medical
School, Edinburgh, UK; University of Split Medical School and
University Hospital ‘‘Sestre Milosrdnice’’, Croatia; Queen’s
Medical Centre, Nottingham, UK; Queen’s University Belfast,
Northern Ireland, UK; University of Bristol, Frenchay Hospital,
UK; University of Manchester, UK; University of Oxford, UK;
Figure 3. In vitro functional effects of variant 3 (rs5786996) on reporter gene expression. Note that variant 3 (-/C) has a single C insertion.
Thus the major allele is indicated by a – and the minor allele by a C. pGL3P constructs containing v3 sequence were transfected into (A) Be(2)-C and
(B) HepG2 cell lines. 59 and 39 refer to the position of the cloned sequences relative to the luciferase gene and promoter in the pGL3P vector.
‘‘-’’=vector containing v3 major allele sequence, ‘‘C’’=vector containing v3 minor allele insertion sequence, ‘‘P’’=pGL3P positive control vector
(containing SV40 promoter), ‘‘B’’=pGL3B negative control vector (containing no promoter). Error bars represent standard error of the mean. Note
that in Be(2)-C cells, the v3 sequence had a repressor effect when compared to the pGL3P positive control vector (P) alone that achieved significance
(59C; fold-change=0.82, p=0.03, 39-; fold-change=0.65, p=0.001; 39C; fold-change=0.19, p,0.0001) for all except the 59- major allele sequence that
showed no significant change in expression. In HepG2 cells, the 59major allele sequence had an enhancer effect (59-; fold-change=1.62, p=0.008)
while the 59C vector showed no significant change in expression compared to P. Both 39 constructs had repressor activity (39- fold-change=0.56,
p=0.0008, 39C fold-change=0.14, p,0.0001).
doi:10.1371/journal.pone.0008764.g003
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obtained for all individuals that participated in this study.
Case-Control Subjects
The age-at-diagnosis/entry, diagnosis method, and percent
female in the LOAD cases and controls for each USA and ART
series are shown in Table S1.
USA Case-Control Subjects
The USA case-control series consisted of 5,173 Caucasian
subjects from the United States (2,513 AD, 2,660 control)
ascertained at the Mayo Clinic (1,811 AD, 2,451 controls) or
through the National Cell Repository for Alzheimer’s Disease
(NCRAD: 702 AD, 209 control). All subjects ascertained at the
Mayo Clinic in Jacksonville, Florida (JS: 632 AD, 660 control) and
at the Mayo Clinic in Rochester, Minnesota, (RS: 576 AD, 1,417
control) were diagnosed by a Mayo Clinic neurologist. The
neurologist confirmed a Clinical Dementia Rating score of 0 for all
JS and RS subjects enrolled as controls; cases had diagnoses of
possible or probable AD made according to NINCDS-ADRDA
criteria [45]. In the autopsy-confirmed series (AUT: 603 AD, 374
control), all brains were evaluated by Dr. Dennis Dickson and
came from the brain bank maintained at the Mayo Clinic in
Jacksonville, FL. In the AUT series the diagnosis of definite AD
was also made according to NINCDS-ADRDA criteria. All AD
brains analyzed in the study had a Braak score of 4.0 or greater.
Brains employed as controls had a Braak score of 2.5 or lower
but often had brain pathology unrelated to AD and pathological
diagnoses that included vascular dementia, frontotemporal
dementia, dementia with Lewy bodies, multi-system atrophy,
amyotrophic lateral sclerosis, and progressive supranuclear palsy.
One AD case from each of the 702 late-onset NCRAD families
was analyzed. NCRAD AD cases were selected based on strength
of diagnosis (autopsy-confirmed: 32%.probable: 45%.possible:
8%.family report: 15%); the case with the earliest age at
diagnosis was taken when several cases had equally strong
diagnoses. The 209 NCRAD controls that we employed were
unrelated Caucasian subjects from the United States with a
Clinical Dementia Rating of 0, specifically collected for inclusion
in case-control series.
Alzheimer’s Research Trust (ART) Case-Control Subjects
Samples from a total of 1,797 subjects were obtained from five
Alzheimer’s Research Trust, UK (ART) network centers, as shown
in Table S1. All samples were from subjects who were diagnosed
clinically using NINCDS-ADRDA criteria [45]. All patients with
evidence of an autosomal dominant AD trait, or where a first
degree relative had been diagnosed with familial AD, were
excluded. Since there were no controls available for the
Manchester series, the Manchester AD samples were combined
with those in the Oxford series when the individual series were
analyzed.
DNA Isolation
For the JS and RS samples, DNA was isolated from whole
blood using an AutoGen instrument (AutoGen, Inc, Holliston,
MA). The DNA from AUT samples was extracted from
cerebellum using WizardH Genomic DNA Purification Kits
(Promega Corp., Madison, WI). DNA from the RS and AUT
series was scarce, so samples from these two series were subjected
to whole genome amplification using the Illustra GenomiPhi V2
DNA Amplification Kit (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ).
For the ART samples, genomic DNA was extracted from whole
blood samples or brain tissue using the QIAamp DNA blood mini
kit (Qiagen, Crawley, West Sussex, UK).
Variant Discovery
Conserved segments in the region encompassing all 25 exons of
IDE and up to 10 kb from the 59 and 39 ends of the gene, were
screened for DNA variation likely to be functional in a subset
of the JS series (269 cases and 252 controls). This sample size
gave us enough power to detect all polymorphisms that occur
at a frequency .1% in this population. The criteria used for
conservation was a cut-off of $70% identity over 100 bp windows
between the human and mouse sequence or between the human
and rat sequence, as determined by the pre-computed align-
ments in the VISTA Genome Browser (http://pipeline.lbl.gov/
cgi-bin/gateway2). The human genome position screened was
chr10:94,335,255-94,475,049 in the Human April 2003 genome
build. The latter build was used as the base genome, and was
compared to the Mouse Feb. 2003 and Rat Jan. 2003 builds.
In each of the 521 subjects screened, we evaluated 40 amplicons
that contained a total of 9,501 bp of conserved DNA. This DNA
included all exons (5,954 bp) as well as conserved regions located
up to 10kb from the gene’s 59 end (268 bp), up to 10kb from the
gene’s 39 end (1,465 bp), and 1,814 bp of highly conserved
intronic sequence. Forty PCR primer pairs were designed to
screen the targeted conserved segments via denaturing high
performance liquid chromatography (dHPLC). PCR amplicons
were generated with 20ng of DNA in a 50ul PCR containing
0.2mM forward primer, 0.2mM reverse primer, 200mM dNTPs, 5ul
of 106reaction buffer with 25mM MgSO4 (Transgenomic, Inc.),
and 1 Unit of OptimaseH Polymerase (Transgenomic, Inc.), using
one of the following three conditions in a Hybaid thermocycler:
60–50 Touchdown, 62–57 Touchdown, or 55–45 Touchdown.
Each PCR product was denatured at 95uC for 10 min and cooled
slowly to 25uC at a rate of 0.03uC/sec to encourage heteroduplex
formation. 5ml of each sample was injected into a DNASepH HT
Cartridge 6.5mm637mm (Transgenomic, Inc.) and analyzed in a
WAVE DHPLC instrument (Transgenomic, Inc.) to identify
heterozygotes. The optimal oven temperature and WAVE
OptimizedH buffer gradient for DHPLC analysis of each amplicon
was selected using the Navigator
TM software (Transgenomic, Inc.).
Samples were categorized as either heteroduplexes or homo-
duplexes, based on the resulting elution profiles as recommended
by Transgenomic, Inc. Representative homoduplexes and hetero-
duplexes from each amplicon were sequenced in order to
determine the nature of the DNA variation underlying each
heteroduplex profile. 20ml of remaining PCR product from the
selected samples were purified for the sequencing reaction using
the MultiScreenH PCR96 Filter Plates (Millipore). Sequencing in
the forward and reverse orientation was performed at the
Molecular Biology Core Facility at the Mayo Clinic, Rochester,
MN as described on their website (http://mayoweb.mayo.edu/
mbcf/mbcf/dna_seq.html). This variant discovery effort yielded
53 variants (42 novel, as shown in Table S2) of which 14 had
minor allele frequencies (MAFs) .1%. Twelve of these were
genotyped, 2 could not be converted into TaqMan assays (deep
intronic, 1 base insertions within simple repeats).
To complement our de novo search for conserved variants,
we developed a web based application called SNPMiner to mine
known variants in conserved regions. As input the application
takes a standard NCBI query string and/or a set of chromosomal
coordinates. In real time, the application collects information
from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) on
all variants that satisfy the input. Using VISTA’s pre-computed
IDE eSNP, Ab Levels and AD Risk
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downloaded into our local server, SNPMiner scans all 100 bp
regions encompassing each variant retrieved from dbSNP and
identifies the 100 bp region with maximum identity between the
mouse and human sequence. In this fashion, we identified all
known variants in the IDE gene or its 10 kb flanks that were in
conserved regions with human vs. mouse sequence identity .70%.
The variants in conserved regions that had MAF information in
dbSNP were genotyped, as described below in the section entitled
‘‘Genotyping of IDE variants’’, in at least the Mayo JS series
to determine if they met the MAF cut-off of $0.01. In the case of
variants that did not have MAF information in dbSNP, dHPLC
was used as described above to estimate their frequency. In the JS
series, HaploView [46] was employed to determine the degree of
linkage disequilibrium between the variants identified through our
de novo search that could be genotyped with TaqMan assays.
Our review of all known IDE variants identified 15 additional
variants, each located in a 100 bp region that had sequence
identity of $70% between the mouse and human sequence. Of
these, 8 had MAFs$1%. Three of these were in perfect LD with
variants from the de novo search, thus were eliminated (Variant
IDs 925, 931 and 934, Table S2) leaving 17 common IDE
variants in conserved regions to be genotyped. The location of the
68 IDE variants in conserved regions is shown relative to gene
structure in Figure S1a. The locations of the 17 common variants
that were genotyped are shown in Figure S1b. All 68 conserved
variants are fully described in Table S2, where the 17 variants
that were genotyped are shown in boldface type.
Genotyping of IDE Variants
Variants found in conserved regions via dHPLC and those
found in dbSNP having known MAFs were selected for
genotyping. Conserved variants in dbSNP without known MAF
were genotyped only if they were observed at least once via
dHPLC analysis of 182 subjects. All genotyping of USA series
samples was performed at the Mayo Clinic in Jacksonville using
TaqManH SNP Genotyping Assays in an ABI PRISMH 7900HT
Sequence Detection System with 384-Well Block Module from
Applied Biosystems, California, USA. The genotype data was
analyzed using the SDS software version 2.2.2 (Applied Biosys-
tems, California, USA).
The ART data, was also generated with TaqMan assays
performed at Geneservice (Cambridge, UK). Fifteen percent of
the samples assayed were of known genotype, determined by
sequencing, which were unknown to Geneservice, but known at
source and 10% were genotyped in duplicate as a quality
assurance measure. The data were only accepted when there
was 100% concordance between duplicate samples.
Details of the variants investigated in this study, including
location, MAF, Hardy-Weinberg equilibrium p values and
genotype counts can be found in Table S3.
IDE Haplotypes
Analysis by HaploView [46] (solid spine of LD) showed that the
17 IDE variants were in strong linkage disequilibrium (Figure
S1c). These variants formed 11 haplotypes (Table S4) with a
frequency of 1.0% or more that could be identified with 10 tagging
variants. Analysis by Haplo.Stats identified the same 11 haplo-
types, which accounted for 96% of the IDE genetic variation
captured by the 17 variants. Haplotype frequencies were estimated
using the expectation-maximization approach implemented in the
haplo.em function of haplo.stats v1.2.2 [47]. Haplo.stats was also
used to create files showing the inferred haplotypes for each
individual, which were used to perform logistic regression analyses.
Measurement of IDE mRNA Expression
Total RNA was extracted from samples of cerebellum from 200
AD brains using an ABI PRISM 6100 Nucleic Acid PrepStation
and the Total RNA Isolation Chemistry kit from Applied
Biosystems. RNA was reverse transcribed to single-stranded
cDNA using the High-Capacity cDNA Archive Kit from Applied
Biosystems. Real-time quantitative PCR was performed in
triplicate for each sample using ABI TaqMan Low Density
expression Arrays (384-Well Micro Fluidic Cards) with a pre-
validated TaqMan Gene Expression Assay. 18s ribosomal RNA
(18s rRNA) was used as the endogenous control for the relative
quantification of IDE mRNA. Real-time PCR cycle threshold (CT)
raw data was collected and exported using the ABI PRISMH SDS
software version 2.2.
The variable CT within the raw data file indicates the PCR
cycle number at which the amount of amplified gene target
reaches a fixed threshold. The variable DCT denotes the difference
between the averaged CT values for the IDE transcript and that for
the reference 18S rRNA transcript.
The DCT values calculated from each sample were used as
quantitative phenotypes to determine associations between IDE
variants and the level of IDE transcript. Some samples had one or
more replicate measurements that failed to amplify and were
obvious outliers, thus they were excluded from the analysis. All
samples included for analysis had at least two replicates with a
SEM #0.35.
Association of IDE Haplotypes and Variants with the
Level of IDE Transcript
The fold difference in the expression levels for the minor allele
was estimated from the regression coefficient (ß) for the additive
model that was fit to the DCT data, which were expressed on the
log2 scale, while also adjusting for APOE e4 dosage, age at
diagnosis/entry and sex. Therefore, we summarized the associa-
tions using 2
(2ß) to estimate the fold difference in expression due to
a single copy of the minor allele, and 2
[2(ß62SEM)] to estimate the
corresponding 95% confidence interval (CI). We further summa-
rized the expression differences graphically by preparing box plots
showing the relative amount of IDE transcript in any sample in the
series as compared to the mean expression level of all of the
samples that were major homozygotes. This was done by
computing the mean of all DCT values for the samples in the
major homozygote category and subtracting it from each of the
DCT values for all samples in all genotype categories (i.e. major
homozygotes, heterozygotes and minor homozygotes) to obtain
DDCT values. Given that these DDCT values are the log2 fold
changes between two measurements, the relative expression levels
between any sample and the mean of the major homozygotes is
given by 2
2DDCT =2 ˆ(2(DCT_Any Sample2mean(DCT_Major
Homozygotes))). These 2
2DDCT values are plotted in the box plots.
The overall association between estimated haplotypes (frequen-
cy .0.01 in combined dataset) and the level of IDE transcript
(DCT) was determined by multivariable linear regression using a
haplotypic dosage model with sex, age at diagnosis/entry, and
APOE e4 dosage (0, 1 or 2 copies of the e4 alelle) as covariates. The
association between individual haplotypes and IDE transcript
(DCT) was determined by linear regression using an allelic dosage
model with sex, age at diagnosis/entry, and APOE e4 dosage as
covariates. The haplo.stats package was used to create the files
containing the inferred haplotypes for each individual that were
used to perform these analyses.
IDE variants were analyzed for association with the level of IDE
transcript (DCT) using an additive/allelic dosage (11=0, 12=1,
IDE eSNP, Ab Levels and AD Risk
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entry, APOE e4 dosage and series as covariates.
Power to Detect Association between IDE Variants and
the Level of IDE Transcript
In our AUT series, we obtained IDE transcript levels from
194 LOAD brains. Using power formulae for an ordinal test
of significance across the three possible genotypes using linear
regression, we computed the detectable effect size while setting the
power at 80% for a 0.05 level test for selected minor allele
frequencies. Although the identified variants were in high LD, we
re-computed these estimates after correcting for the 17 tests
performed. With the sample size available to us, and with the
minor allele frequencies of the IDE variants, we had 80% power to
detect differences in DCT values at least 1.11, 0.48 and 0.30
standard deviations for variants with MAFs of 1.7%, 10.3% and
35.5%, respectively. After applying Bonferroni corrections for 17
variants, these detectable effect sizes climbed to 1.52, 0.65 and
0.41. Given that the standard deviation of the DCT values is 1.13,
these detectable effect sizes correspond to fold-differences between
carriers and non-carriers of 2
1.136effect. For the tests performed at
the nominal level, for example, we had 80% power to detect a
2
1.1361.11=2.39-fold per-copy effect for the most rare variant and
a 1.29-fold per-copy effect for the most common variant.
Association of IDE Haplotypes and Variants with LOAD
The overall association between haplotypes (frequency .0.01 in
combined dataset) and LOAD was determined using the global
score statistic implemented in the haplo.score function incorpo-
rated in the haplo.stats package [47] while adjusting for sex, age
at diagnosis/entry, APOE e4 dosage, and series effects. The
association between individual haplotypes and LOAD was
determined by entering the estimated haplotypes for the cases
and controls into univariate logistic regression using a haplotypic
dosage model that adjusted for sex, age at diagnosis/entry, APOE
e4 dosage, and series as covariates.
IDE variants were analyzed for association with LOAD by
logistic regression using PLINK software [48] with sex, age at
diagnosis/entry, and APOE e4 dosage as covariates. For logistic
regression using data from the combined series, we also included
indicator variables for the individual series as covariates. All
logistic regression analyses were performed using the additive/
allelic dosage model as the primary test of significance for each
variant. To test for evidence of any series-related effects on these
associations, we compared this model to one that also incorporated
series x genotype interactions in addition to all previously
mentioned covariates. This analysis showed no evidence for
series-related effects on any of the associations.
Power to Detect Association between IDE Variants and
LOAD
We have assembled the largest case-control series for LOAD
genetic association studies available to date. In our combined
series, we obtained samples from 3,529 cases and 3,441 controls.
The minor allele frequencies (MAFs) of the 17 IDE variants
identified in the conserved regions of the gene ranged from 1.7%
to 35.5% with a median of 10.3%. Using power for the Armitage
test for trend [49], we computed the minimum odds ratios (ORs)
greater than one, and the maximum ORs less than one, that could
be detected in a sample of this size while setting the power at 80%
for a 0.05 level test. Although the identified variants were in high
LD, we re-computed these estimates after a Bonferroni correction
for the 17 tests performed. With the sample size available to us,
and with the minor allele frequencies of the IDE variants, we had
80% power to detect ORs of at least 1.40, 1.17 and 1.11, or no
more than 0.66, 0.85 and 0.90, for variants with MAFs of 1.7%,
10.3% and 35.5%, respectively. After applying Bonferroni
corrections for 17 variants, the ORs greater than one climbed to
1.54, 1.22 and 1.14 and the ORs less than one dropped to 0.57,
0.80 and 0.87.
Linkage Disequilibrium between rs6583817 (v311) and
rs7910977
We previously conducted a LOAD genome wide association
study (GWAS) with 313,504 SNPs in 844 cases and 1,255 controls
that were also analyzed for association with the 17 IDE variants in
conserved regions [10]. HaploView 3.1 was used to calculate the
extent of LD between these 17 variants and the GWAS SNPs
located in IDE or its 100 kb flanking regions. This analysis showed
that GWAS SNP rs7910977 was in strong linkage disequilibrium
with v311 (r
2=0.996 and D9=1) identified in the current study.
The measurements of IDE transcript levels described in the
‘‘Measurement of IDE mRNA expression’’ section above included
174 cerebellar samples obtained at autopsy from subjects that were
part of our LOAD GWAS. Consistent with the results we report
for v311, rs7910977 associated strongly with the level of IDE
transcript in these 174 samples with a p value of 2.7610
28 that
was significant at the genome-wide level. rs7910977 also showed
significant association with LOAD in the 2,099 subjects analyzed
in the GWAS (p=0.005).
Association of rs7910977 with Plasma Ab40 and Ab42
rs7910977 was genotyped as part of two genome-wide
association studies of the Dalmatian island populates of Vis and
Korcula, using Illumina genotyping platforms [42,44]. Genotypes
for this SNP were present (following quality control) for 883 of
the 949 subjects with plasma Ab measurements in the Vis study
and 876 of the 930 subjects with plasma Ab measurements in
the Korcula study. Study samples from Vis and Korcula were
collected as described previously [42,44] and plasma levels of the
Aß40 and Aß42 peptides were measured, in duplicate, using a well
established sandwich ELISA system, also described elsewhere
[50,51]. Antibody pairs BNT77/BC05 were used to measure
plasma Ab42 in both populations, the BAN50/BA27 pair was
used to measure Ab40 in the Vis population and the BNT77/
BA27 pair was used to measure Ab40 in the Korcula population.
The ELISA assays were repeated for individuals that had a
coefficient of variation (CV) of greater than 0.2 for the duplicate
measurements; following repetition of these measurements the
median value was used as the estimate of the plasma Ab value. A
third trait was created termed ‘‘total Aß’’ by summing these raw
values for Aß40 and Aß42 for each person. This trait was then
analysed in the same manner as the Aß40 and Aß42 traits
individually.
The R package GenABEL [52] was used for association analysis
where a kinship matrix was generated using genotypic data from
the genome wide scan to control for relatedness of the study
participants. The distribution of data values for Aß40, Aß42 and
totalAß did not meet the assumption of normality and so a rank
transformation was implemented in GenABEL to normalize the
data distributions. Using the polygenic and mmscore functions
available in GenABEL we tested the additive effect of the minor
allele (T) for this SNP on the transformed plasma Aß phenotypes
including covariates for age and sex in the model. Using the
functions available in the related R package MetABEL (http://
mga.bionet.nsc.ru/,yurii/ABEL/) we performed meta analysis
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this analysis are shown in Table S5.
Preparation of IDE v311 Construct
A 149bp fragment containing v311 was cloned into a luciferase
pGL3 vector containing an SV40 promoter (Promega) using the
Gateway cloning system (Invitrogen). AttB-flanked primers specific
to a 149bp region surrounding v311 (forward 59 GGGGA-
CAAGTTTGTACAAAAAAGCAGGCT-TGGTCATTTTGGA-
GATGTGG 39, reverse 59 GGGGACCACTTTGTACAAGAA-
AGCTGGGT-TCACACAGCATTGTTTTCCA 39) were used
to amplify genomic DNA extracted from individuals known to be
homozygous for v311 major or minor allele. PCR reactions were
performed in a reaction mix containing 1xPCR buffer containing
1.5mM MgCl2 (QIAGEN), 1mM dNTPs (Promega), 0.2mM each
primer, 2.5U HotStar Taq DNA polymerase and 20ng genomic
DNA to a final volume of 25ml. Amplification conditions were as
follows; 95uC for 5 minutes, followed by 35 cycles of 95uC for
30 seconds, 54uC for 1 minute, 72uC for 1 minute and finally an
extension step of 72uC for 10 minutes. The resultant amplicons
(major and minor allele) were extracted from an ethidium
bromide-stained agarose gel using a QIAquick Spin kit (QIAGEN)
and verified by sequencing (Mayo Clinic, Rochester). The attB-
flanked fragments were integrated via bacterial recombination into
a kanamycin-resistant pDONR 221 vector using the BP Clonase II
system (Invitrogen) to produce an entry clone. Entry clones were
transformed into Library efficiency DH5a chemically competent
E.coli (Invitrogen) and grown on LB agar containing 50mg/ml
kanamycin overnight at 37uC. Single colonies were picked for
inoculation in liquid LB broth containing 50mg/ml kanamycin and
incubated overnight in a shaking incubator at 37uC. Plasmids were
extracted from the bacterial cells using a QIAprep spin kit
(QIAGEN). Final expression clones were constructed by recom-
bination of the entry clones with ampicillin-resistant pGL3
promoter vector using the LR Clonase II system (Invitrogen).
Expression clones were transformed into DH5a E.Coli and grown
on LB agar containing 100mg/ml ampicillin and single colonies
were inoculated in LB broth containing 100mg/ml ampicillin.
Plasmids were extracted using endotoxin-free Zyppy Plasmid
miniprep kit (Zymo research) and verified by sequencing. Four
expression clones were made in total; 59G and 59A contained 311
major (G) or minor (A) sequence positioned 59 to the SV40
promoter and luciferase reporter gene, 39G and 39A contained
sequence positioned 39 to the luciferase gene.
Cell Culture
Human HepG2 hepatocellular carcinoma and Be(2)-C neuro-
blastoma immortalized cell lines were supplied by ATCC. Cells
were cultured in Eagle Minimum Essential Medium (EMEM)
supplemented with 10% fetal bovine serum, 2mM L-Glutamine,
16non-essential amino acids, 1000U/ml Penicillin-Streptomycin
(Sigma), 2.5mg/ml Fungizone (Invitrogen). All cultures were
incubated at 37uCi n5 %C O 2.
Transfections
1610
5 Be(2)-C cells or 3610
5 HepG2 cells were plated in12-
well culture plates 24 hours before transfection. Cells were co-
transfected in triplicate with the v311 luciferase expression clones
and a pRL vector (Promega) containing Renilla Luciferase
reporter gene. Control wells included co-transfection of either
pGL3 B (empty pGL3vector) or P (containing the SV40 promoter)
with pRL. On day of transfection, cells were washed62 with PBS
and media was replaced with 400ml serum-free EMEM contain-
ing 200ng expression clone or control vector, 10ng pRL and
transfection reagent Tfx-20 (Promega) at a charge ratio of 3:1
(Tfx:DNA) per well. Transfection mix was pre-incubated for
15 minutes at room temperature. One hour after transfection,
800ml complete EMEM was added to each well.
Dual Luciferase Assay
48 hours after transfection, cells were washed62 with PBS and
harvested with 200mlo f1 6Lysis buffer (Promega) for 20 minutes
on a rocking platform. 5ml lysate was plated in a white 96-well
assay plate. Firefly and Renilla luciferase signal were measured on
a Veritas microplate luminometer (Turner Biosystems) using the
Dual luciferase reporter assay system (Promega). The ratio of
Firefly to Renilla luciferase signal was used to normalize firefly
activity for intra-experimental transfection efficiency. Unpaired t-
tests comparing mean relative firefly signal for our expression
clones were performed using Stats Direct.
Web Resources
dbSNP: http://www.ncbi.nlm.nih.gov/projects/SNP/References
Alzgene: http://www.alzforum.org/res/com/gen/alzgene/default.
asp
Supporting Information
Text S1 Discussion of single variant and haplotypic associations.
Supplementary note.
Found at: doi:10.1371/journal.pone.0008764.s001 (0.04 MB
DOC)
Figure S1 Location and LD of common conserved IDE variants.
(a) Location of the 68 IDE variants that meet conservation criteria
(red vertical lines, conservation .70% identity over 100 bp
bewteen human and mouse) is shown relative to IDE exons (blue
boxes) and UTRs (green boxes). The gene structure is shown in the
59 to 39 orientation from p- to q-telomere. (b) Location of the 17
IDE variants that meet conservation and MAF criteria
(MAF.1%). (c) HaploView LD D9 plot (solid spine block
definition) and the 11 common haplotypes (frequency.1%)
formed by these 17 variants.
Found at: doi:10.1371/journal.pone.0008764.s002 (0.20 MB
DOC)
Table S1 Details of samples used in this study. The number of
AD patients (AD) and controls (CTRL), mean age, percentage that
are female are given for each individual and pooled series. Mean
age is given as age at diagnosis/entry. The standard deviation (SD)
from the mean is given in parenthesis.
Found at: doi:10.1371/journal.pone.0008764.s003 (0.07 MB
DOC)
Table S2 Description of IDE conserved variants. Details for the
68 variants identified in our conserved variant screen are provided.
The 17 common, conserved variants tested are in bold. Variant
ID=‘‘In house’’ unique variant identifier. rs=dbSNP variant
identifier. Position=Chromosomal position based on the Human
Genome build 36.1. Location=Variant location relative to the
gene structure. a. a. Change=type of amino acid change
predicted for variants within exons. Cons max=maximum
conservation of any 100 bp window containing the variant. Study
MAF=minor allele frequency in the combined USA+ART case
control series. dbSNP MAF=minor allele frequency reported by
dbSNP as of 10-17-08 (from HapMap-CEU, except for rs1042444
which only had CEPH MAF). dbSNP MAF: VNA=variant not
present in dbSNP. dbSNP MAF: NA=MAF not reported in
dbSNP. Source: a=found via dHPLC screen; b=found via
SNPMiner; c=found via SNPMiner, but confirmed via dHPLC;
IDE eSNP, Ab Levels and AD Risk
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variant found via SNPMiner.
Found at: doi:10.1371/journal.pone.0008764.s004 (0.04 MB
XLS)
Table S3 IDE variant information. The position of each variant
is indicated relative to the Human Genome build 36.1. The
columns labeled as 1 and 2 indicate the major and minor allele,
respectively, and 11, 12, 22 indicate the corresponding genotype
counts in all USA and ART combined series for the ten tagging
variants (boldface type) and in the USA series for the remaining 7.
MAF=minor allele frequency in Controls, Cons=conservation,
rs=dbSNP variant identifier, HWp=Hardy-Weinberg p value in
controls.
Found at: doi:10.1371/journal.pone.0008764.s005 (0.10 MB
DOC)
Table S4 IDE haplotypes. Haplotypes are numbered according
to their frequency in the USA series. Only haplotypes with
frequency .0.01 are shown. The ‘‘Haplotype’’ and ‘‘Variant ID’’
columns show the allelic composition of each haplotype in the 59
to 39 orientation from the p to the q telomere of chromosome 10.
The allelic composition of each haplotype is depicted as ‘‘0’’ for
major allele and ‘‘1’’ for minor allele. The 10 haplotype tagging
variants are highlighted in bold.
Found at: doi:10.1371/journal.pone.0008764.s006 (0.08 MB
DOC)
Table S5 Illumina variant (rs7910977), which is in complete LD
with v311, showing association with decreased plasma levels of
Ab40 and Ab42. Association with plasma Ab was performed using
multivariable regression analysis providing coefficient values
(negative coefficient represents decrease in plasma Ab levels).
Found at: doi:10.1371/journal.pone.0008764.s007 (0.05 MB
DOC)
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